SCHEMBL22804323

SCHEMBL22804323

CC(O)C1CCN(CCc2ccc(Br)cc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 4/20 0.53
HTR2C P28335 3/20 0.53
HTR7 P34969 1/20 0.53
KDM4E B2RXH2 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
CYP2D6 P10635 1/20 0.52
TSHR P16473 1/20 0.52
SPHK1 Q9NYA1 2/20 0.49
HRH3 Q9Y5N1 1/20 0.49
ACHE P22303 1/20 0.45
HRH1 P35367 2/20 0.45
DRD2 P14416 1/20 0.45
ADRA2B P18089 1/20 0.45
DRD1 P21728 1/20 0.45
ADRA1B P35368 1/20 0.45
OPRK1 P41145 1/20 0.45
HTR2B P41595 1/20 0.45
KCNQ1 P51787 1/20 0.45
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30560122 0.89 HTR2A (0.42) HTR2AHTR2CHTR7KDM4ECYP1A2
SCHEMBL24494918 0.85 HTR2A (0.53) HTR2AHTR2CHTR7KDM4ECYP1A2
SCHEMBL29363711 0.85 HTR2A (0.40) HTR2AHTR2CHTR7KDM4ECYP1A2
SCHEMBL24495147 0.85 KDM4E (0.53) KDM4EHRH3
SCHEMBL24494922 0.80 CCR3 (0.51) SPHK1HRH3
SCHEMBL24495209 0.80 SPHK1 (0.63) HTR2AHTR2CHTR7SPHK1HRH3
SCHEMBL29586876 0.79 KDM4E (0.58) HTR7KDM4ETSHR
SCHEMBL15566417 0.78 HRH3 (0.44) HTR2AHTR2CHTR7KDM4ECYP1A2
SCHEMBL22804324 0.78 CCR3 (0.49) HRH3ACHEKCNH2
SCHEMBL30560124 0.77 KDM4E (0.49) KDM4EHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113993872-B EGFR inhibitors for the treatment of cancer 豪夫迈·罗氏有限公司 2024-09-24 CN disclosed
US-20240018154-A1 NEW INDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-18 US disclosed
US-20240018154-A1 NEW INDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2024-01-18 US disclosed
WO-2022117487-A1 NEW INDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2022-06-09 WO disclosed
EP-3986896-A1 EGFR INHIBITORS FOR THE TREATMENT OF CANCER F. Hoffmann-La Roche AG (CH) 2022-04-27 EP disclosed
WO-2020254572-A1 EGFR INHIBITORS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2020-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018154-A1 NEW INDAZOLE DERIVATIVES CYP3A43, CYP3A4, CYP3A5 HTR2A 2664/4885HTR2C 1202/4885HTR7 1545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.